Dexcom IncDXCM

DexCom’s 10-Q for the quarter ended 31 March 2026 shows a revenue line of $1.19 billion, net income of $199.5 million, and diluted EPS of $0.51 on 393.6 million shares-numbers that look like a diabetes-management company that’s actually managing something. The balance sheet carries $1.12 billion in cash and cash equivalents and $2.96 billion in shareholders’ equity, while liabilities sit at $3.68 billion; the company is liquid but not debt-free. (source: SEC EDGAR 10-Q ending 2026-03-31, URL: https://www.sec.gov/Archives/edgar/data/1093557/000109355726000133/xslF345X06/wk-form4_1783454979.xml)

Cash generation is healthy: net cash provided by operating activities was $525.6 million, more than enough to cover the $76.6 million spent on property, plant, and equipment and still leave change for R&D, which clocked in at $145.3 million. Inventory rose by $65.2 million to $693.6 million-either a deliberate buffer for a product line that ships sensors by the pallet, or a warehouse that’s forgotten how to clear stock. (source: SEC EDGAR 10-Q ending 2026-03-31, URL: https://www.sec.gov/Archives/edgar/data/1093557/000109355726000133/xslF345X06/wk-form4_1783454979.xml)

The company’s G7 CGM system is the marquee product, positioned as “simplifying diabetes management with a small device, accurate real-time glucose readings, and proven results.” The media kit and provider site trot out the same imagery-five smiling users outside, sensors stuck to upper arms-and promise “best-in-class accuracy” and a “growing ecosystem of connected partners.” The marketing collateral is polished, but the product itself is what the cash line confirms: DexCom sells a wearable device people actually wear. (source: Dexcom Continuous Glucose Monitoring - The most accurate CGM system | Dexcom, URL: https://www.dexcom.com/en-us; Dexcom Media Kit | Dexcom, URL: https://www.dexcom.com/en-us/media-kit; Healthcare Professionals, URL: https://provider.dexcom.com)

On 14 May 2026, DexCom told investors it aims for “organic revenue growth of 10%+ every year through 2030” and authorised a $1 billion share-repurchase program, giving the board something shiny to point at while the market decides whether the promise outruns the proof. The buyback window closes no later than 30 June 2026, which gives the optics about two more weeks to glow before the next filing cycle. (source: SEC EDGAR 8-K dated 14 May 2026, URL: https://www.sec.gov/Archives/edgar/data/1093557/000109355726000085/dxcm-20260514.htm)

The stock is listed on NASDAQ under the ticker DXCM and trades under the same SEC CIK 1093557 that feeds the EDGAR filings and company-facts JSON. The SEC submissions JSON shows routine 8-K, 10-Q, and shareholder documents, but none of the filings so far explain why the R&D budget is $145.3 million while the EPS is $0.51, or why the inventory line is a six-figure moving part each quarter. Until the company ties the marketing story to the cash story in a way the filings can verify, the gap between the glossy brochure and the balance sheet will remain the most accurate reading of all. (source: SEC EDGAR submissions JSON for CIK 1093557, URL: https://data.sec.gov/submissions/CIK0001093557.json; SEC EDGAR company-facts JSON for CIK 1093557, URL: https://data.sec.gov/api/xbrl/companyfacts/CIK0001093557.json)

For investors trying to decide whether this is a durable franchise or a marketing machine with a sensor-shaped engine, the decisive evidence will sit in the next 10-Q: revenue growth that keeps pace with the $1 billion buyback, R&D that visibly feeds new products, and inventory that stops gyrating like a glucose trace after a midnight snack. Until then, the spread between the pitch deck and the cash register is the only number that matters. (source: SEC EDGAR index for CIK 1093557, URL: https://www.sec.gov/edgar/browse/?CIK=1093557)